» Articles » PMID: 35898604

Depletion of Foxp3 Regulatory T Cells Augments CD4 T Cell Immune Responses in Atherosclerosis-prone Hypercholesterolemic Mice

Overview
Journal Heliyon
Specialty Social Sciences
Date 2022 Jul 28
PMID 35898604
Authors
Affiliations
Soon will be listed here.
Abstract

Compelling evidence suggests a crucial role for Foxp3 regulatory T cells (Tregs) in the control of atherosclerosis. Although suppression of pro-inflammatory CD4 T cell immune responses is supposed to be important for athero-protective action of Foxp3 Tregs, few studies have provided direct evidence for this protective mechanism. We investigated the impact of Foxp3 Treg depletion on CD4 T cell immune responses and the development of atherosclerosis under hypercholesterolemia. We employed DEREG (depletion of regulatory T cells) mice on an atherosclerosis-prone low-density lipoprotein receptor-deficient ( ) background, which carry a diphtheria toxin (DT) receptor under the control of the gene locus. In these mice, DT injection led to efficient depletion of Foxp3 Tregs in spleen, lymph nodes and aorta. Depletion of Foxp3 Tregs augmented CD4 effector T cell immune responses and aggravated atherosclerosis without affecting plasma lipid profile. Notably, the proportion of pro-inflammatory IFN-γ-producing T cells were increased in spleen and aorta following Foxp3 Treg depletion, implying that Foxp3 Tregs efficiently regulate systemic and aortic T cell-mediated inflammatory responses under hypercholesterolemia. Unexpectedly, Foxp3 Treg depletion resulted in an increase in anti-inflammatory IL-10-producing T cells, which was not sufficient to suppress the augmented proinflammatory T cell immune responses caused by reduced numbers of Foxp3 Tregs. Our data indicate that Foxp3 Tregs suppress pro-inflammatory CD4 T cell immune responses to control atherosclerosis under hypercholesterolemia.

Citing Articles

Immune cell-mediated features of atherosclerosis.

Liu T, Chen Y, Hou L, Yu Y, Ma D, Jiang T Front Cardiovasc Med. 2024; 11:1450737.

PMID: 39234608 PMC: 11371689. DOI: 10.3389/fcvm.2024.1450737.


Treg Immunomodulation Contributes to the Anti-atherosclerotic Effects of Huxin Formula in ApoE Mice.

Ou X, Cai J, Hu X, Zeng Q, Lan T, Jiang W Chin J Integr Med. 2024; 30(10):896-905.

PMID: 38753277 DOI: 10.1007/s11655-024-3663-2.


Targeting immune cell recruitment in atherosclerosis.

Doring Y, van der Vorst E, Weber C Nat Rev Cardiol. 2024; 21(11):824-840.

PMID: 38664575 DOI: 10.1038/s41569-024-01023-z.


Novel UV-B Phototherapy With a Light-Emitting Diode Device Prevents Atherosclerosis by Augmenting Regulatory T-Cell Responses in Mice.

Tanaka T, Sasaki N, Krisnanda A, Shinohara M, Amin H, Horibe S J Am Heart Assoc. 2024; 13(2):e031639.

PMID: 38214259 PMC: 10926836. DOI: 10.1161/JAHA.123.031639.

References
1.
Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez F . Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2003; 108(10):1232-7. DOI: 10.1161/01.CIR.0000089083.61317.A1. View

2.
Sasaki N, Yamashita T, Kasahara K, Fukunaga A, Yamaguchi T, Emoto T . UVB Exposure Prevents Atherosclerosis by Regulating Immunoinflammatory Responses. Arterioscler Thromb Vasc Biol. 2016; 37(1):66-74. DOI: 10.1161/ATVBAHA.116.308063. View

3.
Tardif J, Kouz S, Waters D, Bertrand O, Diaz R, Maggioni A . Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019; 381(26):2497-2505. DOI: 10.1056/NEJMoa1912388. View

4.
Dinh T, Kyaw T, Kanellakis P, To K, Tipping P, Toh B . Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Circulation. 2012; 126(10):1256-66. DOI: 10.1161/CIRCULATIONAHA.112.099044. View

5.
Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V . Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011; 365(22):2067-77. DOI: 10.1056/NEJMoa1105143. View